Erythropoietin stimulating factors for microangiopathic hemolytic anemia – pro
Microangiopathic anemias anemias are frequently secondary to vascular disease (e.g. vasculitis, hemangiosarcoma, vscular injury, such as older mechanical heart valves, ) or disseminated intravascular coagulation (DIC). Unlike typical hemolytic anemias,eruthropoietin levels can be decreases when with the primary disease concurrently suppress the bone marrow. Occult cancer is a known cause as well.
There are several reports on effectiveness of recombinianty human erythropoietin in trating variosu types of microangiopathic anemia, including those of unknowns cause, and caused by heart valves.
Lechner K, Obermeier HL (July 2012). “Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases”. Medicine 91 (4): 195–205
Macartney CA, Adgey AA, Jones FG, Morris TC, McMullin MF. Novel uses for recombinant erythropoietin therapy in unlicensed indications.Hematol J. 2004;5(2):181-5.
S. Hirawat et al, Recombinant human erythropoietin use in hemolytic anemia due to prosthetic heart valves: A promising treatment. AMERICAN JOURNAL OF HEMATOLOGY 66(3):224-6 · FEBRUARY 2001